Precigen, Inc. (PGEN)
Develops gene and cell therapies to treat cancer and immune disorders using modified viruses and engineered immune cells.
$5.43-0.02%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+225.1%
The outlook
PGEN is trading at $5.43, sitting well above both its 50- and 200-day moving averages and positioned near the upper end of its 52-week range. Analyst price targets average roughly double the current price, though coverage depth isn't specified here. The overall data backdrop shows a bullish technical setup relative to recent trends.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range86% of the way from its 52-week low to high
Price targetAvg target +129% vs current price
Analyst price target
~12-month · 2 analysts$12.45average target+129.3% vs now
Now $5.43
Low $11.00High $13.90
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.94B
52-wk high
$6.04
52-wk low
$1.62
50-day avg
$4.84
200-day avg
$4.24
Trailing P/E
—